Cancer, second only to heart disease, is one of the most expensive conditions to treat. Costs for treatment continue to rise and this can affect patients adversely through a phenomenon know as financial toxicity (FT). Studies utilizing real-world evidence (RWE), real-world data (RWD) and clinical research have established FT as a major factor that can affect the outcomes and quality of life of patients suffering from different cancers and receiving specific treatments. An emerging body of published evidence suggests treatment-related expenses can drastically affect patient well-being and clinical outcomes. Read more here.
(Source: Daniel Vorobiof, Managed Healthcare Executive, September 15, 2020)